The company’s lead drug candidate for Alzheimer’s Disease (AD), ANAVEX 2-73, has successfully completed a Phase 1 single ascending dose clinical trial.
China Analyst, a financial information website focused on U.S.-listed Chinese stocks, recently released its list of the top 10 pharmaceutical stocks with the highest upside.
If dementia care were a company, it would be the world’s largest in terms of annual revenue, surpassing even Wal-Mart.
OneMedPlace announced that it will showcase to investors and entrepreneurs the newest and most promising new medical technologies in the region.
While biotech leaders from all over the world gathered at the 2009 BIO International Convention in Atlanta, financing activity in the sector raised hope that the cloud hanging over the industry may be lifting a little.